WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Country
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
ICLR
ICON PLC
Ireland
$16.83B82,559,36693.75%0.00%
MEDP
MEDPACE HOLDINGS INC
United States
$11.25B31,081,60128.10%71.90%Net SellingNet Buying
FLGT
FULGENT GENETICS INC
United States
$563.41M30,586,81142.95%57.05%Net SellingNet Selling
A
AGILENT TECHNOLOGIES INC
United States
$38.58B287,327,67188.55%1.20%Net BuyingNet Selling
DGX
QUEST DIAGNOSTICS INC
United States
$17.92B111,615,18186.97%1.76%Net SellingNet Selling
TMO
THERMO FISHER SCIENTIFIC INC
United States
$207.28B382,500,26588.56%0.87%Net SellingNet Selling
FONR
FONAR CORP
United States
$104.60M6,654,17446.32%3.54%
CSTL
CASTLE BIOSCIENCES INC
United States
$890.63M28,007,30184.91%15.09%Net SellingNet Selling
DHR
DANAHER CORP
United States
$174.45B722,275,14175.79%24.21%Net SellingNet Selling
NTRA
NATERA INC
United States
$21.25B132,020,81679.22%20.78%Net SellingNet Selling
LAB
STANDARD BIOTOOLS INC
United States
$684.96M372,258,79855.47%44.53%Net BuyingNet Buying
IDXX
IDEXX LABORATORIES INC
United States
$35.20B81,884,66491.35%1.70%Net BuyingNet Selling
SHC
SOTERA HEALTH CO
United States
$4.34B283,239,02966.63%33.37%Net SellingNet Selling
RVTY
REVVITY INC
United States
$14.57B121,702,14590.03%2.57%Net BuyingNet Selling
TWST
TWIST BIOSCIENCE CORP
United States
$2.49B58,585,96087.95%12.05%Net SellingNet Selling
WAT
WATERS CORP
United States
$22.90B59,376,17492.21%7.79%Net Selling
PRPO
PRECIPIO INC
United States
$9.41M1,482,3330.53%99.47%Net BuyingNet Buying
NEO
NEOGENOMICS INC
United States
$2.11B128,360,87172.33%27.67%Net SellingNet Selling
ACRS
ACLARIS THERAPEUTICS INC
United States
$174.29M71,430,94245.45%54.55%Net BuyingNet Selling
SERA
SERA PROGNOSTICS INC
United States
$235.39M33,772,50049.09%13.29%Net SellingNet Selling
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
United States
$10.56B51,136,17896.89%3.11%Net SellingNet Selling
QGEN
QIAGEN NV
Netherlands
$9.55B223,904,00067.72%0.00%
MDXH
MDXHEALTH SA
Belgium
$4.91M27,288,09311.07%88.93%
DRIO
DARIOHEALTH CORP
Israel
$29.43M34,096,35524.03%46.83%Net BuyingNet Buying
NOTV
INOTIV INC
United States
$74.37M26,003,96016.86%48.69%Net Buying
STRR
STAR EQUITY HOLDINGS INC
United States
$10.48M3,234,0990.65%99.35%Net BuyingNet Buying
PSNL
PERSONALIS INC
United States
$335.58M70,648,08431.08%31.30%Net BuyingNet Buying
STIM
NEURONETICS INC
United States
$18.51M30,347,50451.86%48.14%Net BuyingNet Buying
IQV
IQVIA HOLDINGS INC
United States
$38.39B181,500,00053.21%46.79%Net SellingNet Selling
EXAS
EXACT SCIENCES CORP
United States
$9.39B185,076,29396.60%3.28%Net SellingNet Buying
LH
LABCORP HOLDINGS INC
United States
$20.59B83,639,26192.34%1.49%Net SellingNet Selling
APDN
APPLIED DNA SCIENCES INC
United States
$1.87M10,299,3856.55%93.45%
XWEL
XWELL INC
United States
$8.94M5,256,0241.24%98.76%Net BuyingNet Buying
CHEK
CHECK-CAP LTD
Israel
$4.97M5,850,7700.11%0.00%
MTD
METTLER TOLEDO INTERNATIONAL INC
United States
$26.56B21,102,66894.17%4.59%Net SellingNet Selling
NEOG
NEOGEN CORP
United States
$3.29B216,698,13898.60%1.40%Net BuyingNet Buying
PRE
PRENETICS GLOBAL LTD
Hong Kong
$59.65M12,222,3379.76%0.00%
CDNA
CAREDX INC
United States
$1.22B53,633,87178.33%21.67%Net SellingNet Selling
NDRA
ENDRA LIFE SCIENCES INC
United States
$237.19k41,39438.94%61.06%Net BuyingNet Buying
GH
GUARDANT HEALTH INC
United States
$3.91B123,554,61265.06%34.94%Net BuyingNet Selling
MYGN
MYRIAD GENETICS INC
United States
$1.44B91,035,23092.74%7.26%Net SellingNet Selling
XGN
EXAGEN INC
United States
$48.50M17,637,27835.64%64.14%Net Buying
OPK
OPKO HEALTH INC
United States
$1.09B682,483,02918.81%81.19%Net BuyingNet Buying
BNR
BURNING ROCK BIOTECH LTD
China
$35.91M102,596,7062.00%0.00%
ENZ
ENZO BIOCHEM INC
United States
$59.56M52,244,07423.70%47.04%Net Selling
AWH
ASPIRA WOMEN's HEALTH INC
United States
$13.17M16,062,9391.75%98.25%Net Buying
OCX
ONCOCYTE CORP
United States
$39.30M13,368,3878.87%91.13%Net BuyingNet Buying
BDSX
BIODESIX INC
United States
$203.65M145,467,29536.73%52.42%Net BuyingNet Buying
ME
23ANDME HOLDING CO
United States
$111.00M26,117,99784.28%15.72%Net BuyingNet Buying
PRPH
PROPHASE LABS INC
United States
$18.38M23,874,0297.29%43.21%
BIAF
BIOAFFINITY TECHNOLOGIES INC
United States
$17.35M13,449,1652.97%35.09%Net Buying
GRAL
GRAIL INC
United States
$534.92M33,600,77264.25%28.64%Net BuyingNet Buying
VNRX
VOLITIONRX LTD
United States
$70.37M92,101,4798.68%36.86%Net BuyingNet Buying
ISPC
ISPECIMEN INC
United States
$4.14M962,6374.72%95.28%
PMD
PSYCHEMEDICS CORP
United States
$13.66M5,824,03620.37%49.45%
ILMN
ILLUMINA INC
United States
$23.18B158,600,00088.55%2.04%Net BuyingNet Selling
RDNT
RADNET INC
United States
$6.11B74,026,73766.48%33.52%Net SellingNet Selling
GENE
GENETIC TECHNOLOGIES LTD
Australia
$202.29k132,217,2460.19%0.00%
MYNZ
MAINZ BIOMED NV
Germany
$6.40M25,586,5750.40%0.00%
TRIB
TRINITY BIOTECH PLC
Ireland
$11.88M153,310,2841.74%0.00%
MMA
ALTA GLOBAL GROUP LTD
Australia
$20.15M10,282,6860.13%0.00%
TTOO
T2 BIOSYSTEMS INC
United States
$9.58M17,479,9544.57%95.43%Net SellingNet Selling
PMAX
POWELL MAX LTD
Hong Kong
$42.92M14,747,8560.00%0.00%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Nov 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the top diagnostic & research stock with a Zen Score of 45, which is 21 points higher than the diagnostic & research industry average of 24. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock lose -20.63% over the past year, underperforming other diagnostic & research stocks by -8 percentage points.

Icon has an average 1 year price target of $285.50, an upside of 40.02% from Icon's current stock price of $203.90.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Icon, 62.5% have issued a Strong Buy rating, 25% have issued a Buy, 12.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Medpace Holdings (NASDAQ:MEDP)


Medpace Holdings (NASDAQ:MEDP) is the second best diagnostic & research stock with a Zen Score of 44, which is 20 points higher than the diagnostic & research industry average of 24. It passed 15 out of 33 due diligence checks and has strong fundamentals. Medpace Holdings has seen its stock return 31.2% over the past year, overperforming other diagnostic & research stocks by 44 percentage points.

Medpace Holdings has an average 1 year price target of $377.00, an upside of 4.16% from Medpace Holdings's current stock price of $361.94.

Medpace Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Medpace Holdings, 37.5% have issued a Strong Buy rating, 0% have issued a Buy, 62.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) is the third best diagnostic & research stock with a Zen Score of 43, which is 19 points higher than the diagnostic & research industry average of 24. It passed 16 out of 38 due diligence checks and has strong fundamentals. Agilent Technologies has seen its stock return 24.96% over the past year, overperforming other diagnostic & research stocks by 37 percentage points.

Agilent Technologies has an average 1 year price target of $149.18, an upside of 11.1% from Agilent Technologies's current stock price of $134.28.

Agilent Technologies stock has a consensus Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Agilent Technologies, 45.45% have issued a Strong Buy rating, 9.09% have issued a Buy, 36.36% have issued a hold, while 0% have issued a Sell rating, and 9.09% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3%, which is 2 percentage points higher than the diagnostic & research industry average of 0.97%.

Qiagen Nv's dividend payout ratio of 348.8% indicates that its dividend yield might not be sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.84%, which is 1 percentage points higher than the diagnostic & research industry average of 0.97%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 39.4% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) has an annual dividend yield of 0.7%, which is the same as the diagnostic & research industry average of 0.97%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 19.3% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 0.09% in the last day, and down -2.86% over the last week. Natera was the among the top gainers in the diagnostics & research industry, gaining 19.13% yesterday.

Natera shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 59 points higher than the diagnostic & research industry average of 12. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 16.7% in the past year. It has overperformed other stocks in the diagnostic & research industry by 29 percentage points.

2. Fulgent Genetics (NASDAQ:FLGT)


Fulgent Genetics (NASDAQ:FLGT) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fulgent Genetics has a valuation score of 43, which is 31 points higher than the diagnostic & research industry average of 12. It passed 3 out of 7 valuation due diligence checks.

Fulgent Genetics's stock has dropped -29.8% in the past year. It has underperformed other stocks in the diagnostic & research industry by -17 percentage points.

3. Charles River Laboratories International (NYSE:CRL)


Charles River Laboratories International (NYSE:CRL) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Charles River Laboratories International has a valuation score of 29, which is 17 points higher than the diagnostic & research industry average of 12. It passed 2 out of 7 valuation due diligence checks.

Charles River Laboratories International's stock has gained 21.47% in the past year. It has overperformed other stocks in the diagnostic & research industry by 34 percentage points.

Are diagnostic & research stocks a good buy now?

50% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 280.84% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 19.83x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.